HWG Holdings LP Invests $326,000 in Natera, Inc. (NASDAQ:NTRA)

HWG Holdings LP acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,009 shares of the medical research company’s stock, valued at approximately $326,000.

Other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC lifted its stake in shares of Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after purchasing an additional 60,127 shares during the period. Thematics Asset Management raised its stake in Natera by 3.1% during the 4th quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after acquiring an additional 2,738 shares during the period. Russell Investments Group Ltd. raised its stake in Natera by 15.1% during the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after acquiring an additional 9,781 shares during the period. Perceptive Advisors LLC raised its stake in Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after acquiring an additional 632,047 shares during the period. Finally, Natixis bought a new stake in Natera during the 1st quarter worth approximately $758,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Up 1.5 %

NASDAQ NTRA opened at $125.72 on Monday. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The company has a fifty day moving average of $115.98 and a two-hundred day moving average of $106.75. The firm has a market capitalization of $15.44 billion, a price-to-earnings ratio of -40.29 and a beta of 1.53. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $132.01.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period last year, the company earned ($0.97) earnings per share. The business’s revenue for the quarter was up 58.1% compared to the same quarter last year. On average, analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on NTRA shares. BTIG Research raised their target price on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Robert W. Baird increased their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Jefferies Financial Group started coverage on shares of Natera in a report on Monday, June 3rd. They set a “buy” rating and a $142.00 price objective for the company. TD Cowen raised their target price on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, UBS Group cut their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $120.07.

Insider Transactions at Natera

In other news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the sale, the insider now directly owns 284,741 shares in the company, valued at $36,324,409.37. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the sale, the insider now directly owns 284,741 shares in the company, valued at $36,324,409.37. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 499 shares of Natera stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total value of $53,592.60. Following the completion of the sale, the chief financial officer now owns 77,418 shares of the company’s stock, valued at $8,314,693.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,738 shares of company stock worth $5,663,574. 7.60% of the stock is currently owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.